ArticleBMC public health2026
Survival outcomes of older people living with HIV from 2001 to 2020 in Hunan, China: a retrospective cohort study.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe prevalence of HIV is on the rise among older adults, necessitating insights into their distinct characteristics and survival outcomes. This study aims to investigate the survival status and relevant factors among older people living with HIV (OPLHIV).
methodsThis retrospective cohort study extracted data of OPLHIV aged 50 years and older between 2001 and 2020 from the Hunan provincial HIV/AIDS Comprehensive Response Information Management System. Joinpoint regression, Kaplan-Meier, and multivariate Cox proportional hazards regression analytic methods were used for the analysis.
resultsAll-cause mortality among 18,804 participants were 4,446. The median survival time was 175.33 months (95% confidence interval [CI]: 166.01-187.32). Survival rates at months 12, 36, 60, and 120 were 91%, 81%, 74%, and 59%, respectively. From 2001 to 2020, the crude mortality rate among OPLHIV showed an increasing and then decreasing trend, with a turnaround in 2013. Several demographic and clinical factors were associated with a higher risk of all-cause mortality. These include males (HR = 1.644, 95% CI: 1.522–1.776), 70 years and older at the HIV diagnosis (HR = 2.684, 95% CI: 2.472–2.914), farmers (HR = 1.387, 95% CI: 1.223–1.573), unmarried (HR = 1.216, 95% CI: 1.145–1.291), primary school or illiterate (HR = 1.527, 95% CI: 1.351–1.725), heterosexual transmission (HR = 2.134, 95% CI: 1.635–2.787). In addition, clinical characteristics such as baseline CD4 cell counts less than 200 cells/µL (HR = 2.068, 95% CI: 1.833–2.334), not initiating antiretroviral therapy within 30 days of diagnosis (HR = 1.284, 95% CI: 1.209–1.363) were also associated with a higher risk of all-cause mortality.
conclusionsThe overall survival rate of OPLHIV in Hunan, China, is concerning. Enhancing early HIV diagnosis and ensuring rapid initiation of antiretroviral therapy following diagnosis are crucial for improving survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.